Eli Lilly to Slash Insulin Prices, Cap Monthly Out-of-Pocket Costs at $35
By Cara Murez HealthDay Reporter
WEDNESDAY, March 1, 2023 (HealthDay News) -- More Americans will soon be paying less for their insulin.
Eli Lilly, one of the three insulin manufacturers, plans to cut its list prices of the drug by 70% and cap out-of-pocket costs at $35 a month.
"While the current health care system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone, and that needs to change," Eli Lilly CEO David Ricks said in a company statement.
"The aggressive price cuts we're announcing today should make a real difference for Americans with diabetes. Because these price cuts will take time for the insurance and pharmacy system to implement, we are taking the additional step to immediately cap out-of-pocket costs for patients who use Lilly insulin and are not covered by the recent Medicare Part D cap [on insulin costs]," Ricks added.
The company will cut its list price for Humalog 100 units/mL starting in the fourth quarter of 2023.
It will also cut its list price on non-branded Insulin Lispro Injection 100 units/mL, to $25 a vial. That cut will begin May 1, CBS News reported.
People with insurance will have a cap of $35 on out-of-pocket costs when buying the medication at participating retail pharmacies, the company said.
Those without insurance can also pay just $35 a month by downloading the company's Insulin Value Program savings card.
That brings the costs in line with enrollees in Medicare, who had prices capped by the Biden administration’s Inflation Reduction Act last year.
Eli Lilly, Novo Nordisk and Sanofi are the three drugmakers that control the insulin market in the United States. About 3 in 10 people with diabetes use Eli Lilly's insulin.
These drugmakers have been criticized for their high prices, up significantly since they began selling analog insulin products more than 20 years ago, CBS News reported. Some diabetics ration their medication, at great health risk, because of the high price of the medicine.
More information
The American Diabetes Association has more on diabetes.
SOURCES: Eli Lilly, news release, March 1, 2023; CBS News
The news stories provided in Health News and our Health-E News Newsletter are a service of the nationally syndicated HealthDay® news and information company. Stories refer to national trends and breaking health news, and are not necessarily indicative of or always supported by our facility and providers. This information is provided for informational and educational purposes only, and is not intended to be a substitute for medical advice, diagnosis, or treatment.